| Similar Articles |
|---|
 |
Pharmaceutical Executive
October 1, 2011
Atsushi Nagahisa |
Creating Customer Value: It's No Distant Dream The author speaks about how the pharmaceutical industry can fix today's greatest global policy challenge: leveraging hard science to address an enormous -- and growing -- burden of unmet medical need.   |
Pharmaceutical Executive
December 1, 2011
William Looney |
2011: End of the Beginning The gap in perception is one of industry's biggest problems because it adds ballast to the idea that medicines are just a simple procurement item. |
Pharmaceutical Executive
March 1, 2009
Walter Armstrong |
Attack of the Monster Merger Just when you thought it was safe to go back into M&A, the mega merger returns. What's right about Pfizer-Wyeth, and what's scary. |
The Motley Fool
June 20, 2011
Luke Timmerman |
Pfizer's Idea to Fix the Drug Development Crisis, Which Probably Won't Work (But Just Might) In a worst-case scenario, Pfizer flushes a few hundred million dollars down the tubes. What's the best-case scenario? |
CIO
October 28, 2011
Kim S. Nash |
Pfizer's Future Depends on IT Transformation With its business model ailing, this pharmaceutical giant tries a new IT formula, including a loyalty discount card, mobile applications aimed at consumers, and a cloud-based tablet CRM system for physicians. |
BusinessWeek
February 28, 2005
Amy Barrett |
Pfizer's Funk Pfizer CEO Hank McKinnell helped pioneer the age of blockbuster drugs. The company now spends twice as much on sales and administrative expenses as it does on R&D. But a dearth of new products and fears over drug safety are hurting the entire industry. Is there a fix? |
The Motley Fool
December 4, 2006
Michael Leibert |
Whither Pfizer? Bad news follows the upbeat message delivered at Pfizer's R&D briefing. But with strong cash flows, a healthy dividend yield, unparalleled scale, and a discounted share price, Pfizer's risk/reward profile might look attractive to investors. |
The Motley Fool
August 23, 2004
Ben McClure |
Rethinking Big Pharma Risk is knocking Big Pharma stocks down. They won't be getting up anytime soon. Competition, soaring R&D costs, shifting business models, and political meddling combine to make drug stocks a riskier place to invest. |
Pharmaceutical Executive
March 1, 2007
Beth Herskovits |
If I Ran Pfizer The industry is at a crossroads, and all eyes are on the world's largest drug maker. When Pfizer leads, others follow. So we asked: If you had that sort of influence, how would you steer Big Pharma? |
The Motley Fool
September 11, 2007
Brian Lawler |
Looking Forward at Pfizer With generic competition on the way for Pfizer's top drug, Lipitor, the company stepped up to the podium at the Bear Stearns Healthcare Conference this week to let investors know its plans. |
The Motley Fool
October 7, 2004
Brian Gorman |
Pfizer Will Weather the Storm The company will likely come out on top regardless of the outcome of the latest controversies. Pfizer remains a quality choice for long-term investors. |
Chemistry World
May 14, 2014
Andy Extance |
Pfizer presses hard for AstraZeneca deal US pharma giant Pfizer is battling a backlash of suspicion and hostility across the world over its attempts to acquire its UK-headquartered rival AstraZeneca. |
The Motley Fool
October 15, 2007
Brian Lawler |
Save Your Cash, Pfizer A multibillion-dollar stake in Sanofi wouldn't fix Pfizer's problems. Investors, take note. |
The Motley Fool
January 15, 2009
Robert Steyer |
For Pfizer, a Big Buy Could Be a Big Mistake Pfizer's CEO says the company must make a big, bold buy to reverse course on its skidding stock and to blast it out of its revenue doldrums. Is it the right move? |
Chemistry World
February 2, 2011
Andy Extance |
Pfizer to close historic UK site Most of the 2400 people employed at the Pfizer site in Sandwich, UK, will be made redundant over the next 18-24 months as the US pharma giant restructures its research operations. |
The Motley Fool
January 14, 2008
Brian Lawler |
Worst Stock for 2008: Pfizer This analyst thinks that Pfizer is a good company, but a bad stock for 2008. |
The Motley Fool
November 17, 2008
Rich Smith |
This Just In: Upgrades and Downgrades Bank of America analysts aren't terribly impressed with most drug companies. But they did give thumbs up to two. |
The Motley Fool
December 19, 2005
Stephen D. Simpson |
Pfizer Wins, a Sector Rejoices The pharmaceutical dodges a bullet and investors find renewed enthusiasm for big-cap pharma. |
The Motley Fool
November 30, 2011
Brian Orelli |
3 Things More Important to Pfizer Than Losing Lipitor It's not like we didn't see it coming. |
The Motley Fool
April 5, 2005
Stephen D. Simpson |
Pfizer Pfaces Its Pfuture Analysts and investors seem happy with Pfizer's long-term strategy. Should they be? |
The Motley Fool
February 22, 2007
Brian Lawler |
Dueling Fools: Pfizer Bear It's been a blue chip for years, but that doesn't mean it will stay that way forever. It's inconceivable for Pfizer's market capitalization to be valued at $188 billion four years from now, when its revenues could be 40% lower than they are today. |
The Motley Fool
October 20, 2006
Brian Lawler |
Pfizer Keeps Fighting If Pfizer's management can succeed on its cost-savings initiatives and maintain the high single digits of earnings-per-share growth that it expects in 2007-2008, then Pfizer may make a good investment for those willing to wait for the company's new drugs to bring back higher growth. |
The Motley Fool
April 19, 2006
Brian Gorman |
Pfizer Inches Forward The pharma continues on cost-cutting and gives back to shareholders, but R&D productivity remains a tough challenge. |
The Motley Fool
April 21, 2008
Brian Lawler |
Pfizer Is Still Floundering Generic competition keeps pounding away at its sales and profits. |
